Total trials
24
Active
1
Phase 3
5
Total enrollment
1,873
Pipeline matrix
Showing 3 of 3 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Bendamustine | — | — | — | — | — | 2 | |
| Gemcitabine | — | — | — | — | — | 1 | |
| Duvelisib | — | — | — | 13 |
Next readouts
- 2028-02
Top conditions
- Healthy4
- Chronic Lymphocytic Leukemia4
- Small Lymphocytic Lymphoma4
- Lymphoma3
- Follicular Lymphoma3
- Indolent Non-Hodgkin Lymphoma2
- Lymphoma, Small Lymphocytic2
- Head and Neck Squamous Cell Carcinoma1
Frequently asked questions about SecuraBio
- How many clinical trials does SecuraBio have on ClinicalTrials.gov?
- SecuraBio is listed as the lead sponsor on 24 clinical trials in ClinicalTrials.gov, 1 of which are currently active (recruiting, enrolling, or ongoing).
- How many of SecuraBio's trials are in Phase 3?
- 5 of SecuraBio's trials are in Phase 3, spread across 3 active drug programs.
- What therapeutic areas does SecuraBio focus on?
- SecuraBio's most-studied conditions on ClinicalTrials.gov are Healthy, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Lymphoma, Follicular Lymphoma.
- When are SecuraBio's next clinical trial readouts?
- SecuraBio has 1 upcoming primary-completion readout tracked here; the soonest is “A Study of Duvelisib Versus Gemcitabine or Bendamustine in Participants With Relapsed/Refractory Nodal T Cell Lymphoma With T Follicular Helper (TFH) Phenotype”, expected around 2028-02.